Facebook
Twitter
LinkedIn
ForwardDefinitive and Salvage Radiation Therapy for Prostate Cancer
Improvements in technique, as well as advances in technology, have resulted in significant survival advances for those with localized and oligometastatic prostate cancer. In this series we educate learners on how to work in multi-disciplinary teams to provide the highest level of care for their patients which include: rectal spacer/fiducial marker placement, early identification of disease with PSMA PET, aggressive treatments for radiorecurrence and oligometastatic disease.
This educational webinar series offers practical tips for radiation oncologists treating prostate cancer in both the definitive and salvage settings. The first webinar focuses on fiducial/markers placement and incorporating PET imaging findings on radiation planning of prostate cancer. In the second webinar, we evaluate the approach and treatment of oligometastatic prostate cancer. In the third webinar, we review the management of locally radiorecurrent prostate cancer.
TOPICS COVERED:
- PSMA-targeted PET in the Treatment of Prostate Cancer
- Oligometastatic Prostate Cancer
- The Management of Locally Radiorecurrent Prostate Cancer
Please see the Program tab for the session descriptions and presenters.
This activity is available from August 19, 2024 through 11:59 p.m. Eastern time on October 12, 2026.
Target Audience
This activity is designed to meet the interests of radiation oncologists, physicists, radiation dosimetrists, radiation therapists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Describe methods to optimize cure in those with localized or oligometastatic prostate cancer.
- Discuss techniques to mitigate toxicity in the treatment of prostate cancer.
PSMA-targeted PET in the Treatment of Prostate Cancer
— Alexandra Diaz Pardo, MD, MS; Chad Wright, MD, MS, PhD
— Moderators: Shauna McVorran, MD, MHSA and Bhanu Prasad Venkatesulu, MD, MBBS
Rectal spacer and fiducial placement is a valuable method that allows aggressive treatment of localized prostate cancer while simultaneously reducing toxicity. Its success requires advanced procedural skills and work within multi-disciplinary teams. This activity will discuss how to incorporate PET imaging findings on radiation planning of prostate cancer. It will also review the technique for markers placement for prostate cancer.
Oligometastatic Prostate Cancer
— Chad Tang, MD
— Moderators: Shauna McVorran, MD, MHSA and Bhanu Prasad Venkatesulu, MD, MBBS
Radiologic advances and increased availability of SBRT have allowed those with localized/oligometastatic prostate cancer to receive curative therapy that improves survival. Review of new trial data and its application in the clinical setting is imperative to ensure its applicability within the general RO community. In this webinar we review the latest data and current treatment recommendations for oligometastatic prostate cancer.
The Management of Locally Radiorecurrent Prostate Cancer
— Abhishek Solanki, MD, MS
— Moderators: Shauna McVorran, MD, MHSA and Bhanu Prasad Venkatesulu, MD, MBBS
Multiple clinical trials have shown that those with limited prostate cancer benefit from aggressive therapy. Participants learn the latest technologies and techniques that they can offer their patients in their practice including, but not limited to: salvage therapy for radiorecurrent and oligometastatic prostate cancer. In this webinar we review and discuss options for the management of locally radiorecurrent prostate cancer.
- Abhishek Solanki, MD, MS, is employed by Loyola University Medical Center and the Edward Hines Jr. VA Hospital. Dr. Solanki receives grant/research funding from the US Department of Veteran's Affairs. Dr. Solanki serves as an Executive Committee Member with the American College of Radiology.
- Alexandra Diaz Pardo, MD, MS is employed by The Ohio State University. Dr. Diaz receives honoraria as education/meeting faculty from ASTRO and ASCO. Dr. Diaz serves as Vice Chair of DEI with The Ohio State University.
- Chad Tang, MD, is employed by MD Anderson Cancer Center. Dr. Tang receives honoraria from Diffusion Pharmaceutical, Siemen Healthineer, Lantheus, Telix, Molli Surgical and Boston Scientific. Dr. Tang receives grant/research funding from Merck. Dr. Tang owns copyrights/receives royalties from the Stanford Office of Technology Licensing, Wolters Kluwer and Osler.
- Chadwick L. Wright, MD, MS, PhD, is employed by the University of Cincinnati. Dr. Wright serves as a Member of the Board of Directors for the American Board of Science in Nuclear Medicine.
- Shauna McVorran, MD, MHSA, is employed by Geisel School of Medicine at Dartmouth and the Dartmouth Cancer Center.
- Bhanu Prasad Venkatesulu, MD, MBBS, is employed by University of Pittsburgh Medical Center. Dr. Venkatesulu receives grant/research funding from Thomas Gore pancreatic cancer and Gateway to cancer research. Dr. Venkatesulu owns stock in ImmunityBio and Spectrum Pharmaceuticals. Dr. Venkatesulu serves as an Education committee member of ASTRO, a task force mentee with ICRP, an Adhoc member of RadOnc questions, and is a consultant on guidelines with the American Radium Society.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 3.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Live activity for a maximum of 3.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 3.00 Certificate of AttendanceThis activity was designated for 3.00 AMA PRA Category 1 Credit™.
Price
Course fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Member: $199
Member-in-training: $99
Member Student/Grad Student/PGY: $99
Member Postdoctoral Fellow: $99
Nonmember: $299
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until October 12, 2026, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.